Summary of Study ST001423

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000730. The data can be accessed directly via it's Project DOI: 10.21228/M89X1C This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001423
Study TitleAspirin Metabolomics in Colorectal Cancer Chemoprevention - blood (part-III)
Study SummarySubstantial evidence supports the effectiveness of aspirin for cancer chemoprevention in addition to its well established role in cardiovascular protection. In recent meta-analyses of randomized controlled trials in human, daily aspirin use reduced incidence, metastasis and mortality from several common types of cancer, especially colorectal cancer. The mechanism(s) by which aspirin exerts an anticancer benefit is uncertain; numerous effects have been described involving both cyclooxygenase-dependent and -independent pathways. The goal of this research is to elucidate the key metabolic changes that are responsible for the anticancer effects of aspirin in humans using untargeted metabolomics analysis. Metabolomics, or global metabolite profiling, is an emerging discipline that has the potential to transform the study of pharmaceutical agents. Our innovative approach will use high-resolution mass spectroscopy to detect thousands of metabolites in blood plasma that were collected from participants in the Aspirin/Folate Polyp Prevention Study, a randomized, double-blind, placebo-controlled trial of aspirin for the prevention of colorectal adenomas. Participants in the trial were assigned with equal probability to three aspirin treatment arms (placebo, 81mg, or 325mg daily). Over the three-year period, 81mg/day of aspirin reduced the risk of adenomas, whereas the 325 mg/day dose had less effect. The aims of the current proposal are to identify metabolomic signatures, including specific metabolites and metabolic pathways, that are associated with aspirin treatment in blood after three years of randomized aspirin treatment; and then to assess the associations of these metabolic signatures with adenoma risk and whether they mediate the reductions in risk due to 81 mg/day aspirin treatment. We will prioritize metabolites for study by evaluating metabolite levels in patients from the placebo and treatment arms while controlling the false discovery rate, use correlation analysis to enhance identification of relevant metabolic modules associated with these prioritized metabolites, and apply pathway mapping with post-hoc application of ion dissociation spectroscopy to representative metabolites to confirm pathway identification. Because aspirin is a multifunctional drug that is thought to modify numerous pathways with potential roles in carcinogenesis, a global discovery-based metabolomics approach is the best way to identify its key activities. The public health significance of this work is substantial because understanding the mechanism of aspirin's anticancer effects is key to optimizing its use and to the development of novel drugs targeting the metabolic pathways identified.
Institute
Emory University
DepartmentSchool of Medicine
LaboratoryClincal Biomarkers Laboratory
Last NameUppal
First NameKaran
Address615 Michael St, Suite 225
Emailkuppal2@emory.edu
Phone(404) 727 5027
Submit Date2019-11-07
Total Subjects446
Study CommentsAspirin Metabolomics Priority 2
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2020-07-20
Release Version1
Karan Uppal Karan Uppal
https://dx.doi.org/10.21228/M89X1C
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sex Treatment
SA119238400106839_1F 325mg
SA11923940006183_1F 325mg
SA11924040001563_1F 325mg
SA119241400106840_1F 325mg
SA11924240000678_1F 325mg
SA11924340005384_1F 325mg
SA11924440000679_1F 325mg
SA119245400106489_1F 325mg
SA119246400105909_1F 325mg
SA11924740006620_1F 325mg
SA11924840006598_1F 325mg
SA11924940007108_1F 325mg
SA11925040005829_1F 325mg
SA11925140005843_1F 325mg
SA11925240000757_1F 325mg
SA11925340015382_1F 325mg
SA11925440005670_1F 325mg
SA119255400106404_1F 325mg
SA11925640003327_1F 325mg
SA11925740000451_1F 325mg
SA11925840001317_1F 325mg
SA11925940002097_1F 325mg
SA11926040006745_1F 325mg
SA11926140002605_1F 325mg
SA11926240015408_1F 325mg
SA11926340002208_1F 325mg
SA11926440003744_1F 325mg
SA11926540000548_1F 325mg
SA11926640005824_1F 325mg
SA119267400106545_1F 325mg
SA11926840000549_1F 325mg
SA11926940015590_1F 325mg
SA11927040005735_1F 325mg
SA11927140003788_1F 325mg
SA11927240003519_1F 325mg
SA11927340005368_1F 325mg
SA11927440001038_1F 325mg
SA11927540015520_1F 325mg
SA11927640006953_1F 325mg
SA119277400105794_1F 325mg
SA119278400105795_1F 325mg
SA11927940000207_1F 325mg
SA11928040000208_1F 325mg
SA11928140006699_1F 325mg
SA11928240021544_1F 325mg
SA11928340022736_1F 325mg
SA11928440001342_1F 81mg
SA11928540002312_1F 81mg
SA11928640002174_1F 81mg
SA11928740006512_1F 81mg
SA119288400106676_1F 81mg
SA11928940005905_1F 81mg
SA11929040001423_1F 81mg
SA119291400106609_1F 81mg
SA11929240006377_1F 81mg
SA11929340005406_1F 81mg
SA11929440000837_1F 81mg
SA11929540002499_1F 81mg
SA11929640000265_1F 81mg
SA11929740005944_1F 81mg
SA11929840006562_1F 81mg
SA11929940006335_1F 81mg
SA11930040002098_1F 81mg
SA11930140000862_1F 81mg
SA11930240005493_1F 81mg
SA11930340022480_1F 81mg
SA11930440005537_1F 81mg
SA11930540003330_1F 81mg
SA11930640001792_1F 81mg
SA11930740003356_1F 81mg
SA11930840006974_1F 81mg
SA11930940005633_1F 81mg
SA11931040002197_1F 81mg
SA11931140006320_1F 81mg
SA11931240000718_1F 81mg
SA11931340002314_1F 81mg
SA119314400106736_1F 81mg
SA11931540005739_1F 81mg
SA11931640005521_1F 81mg
SA11931740005754_1F 81mg
SA11931840001351_1F 81mg
SA11931940001345_1F 81mg
SA11932040006035_1F 81mg
SA11932140001489_1F 81mg
SA11932240000606_1F 81mg
SA11932340002539_1F 81mg
SA11932440000447_1F 81mg
SA119325400106480_1F 81mg
SA11932640000448_1F 81mg
SA11932740001426_1F 81mg
SA11932840000721_1F 81mg
SA11932940022886_1F 81mg
SA11933040000872_1F 81mg
SA11933140003495_1F 81mg
SA11933240003440_1F 81mg
SA11933340015435_1F 81mg
SA11933440001756_1F 81mg
SA119335400105980_1F 81mg
SA11933640005557_1F 81mg
SA11933740003365_1F 81mg
Showing page 1 of 5     Results:    1  2  3  4  5  Next     Showing results 1 to 100 of 494
  logo